Revelation Biosciences effects 1-for-3 reverse stock split; PRIME Phase 1b enrollment expected to complete July 2025

REVELATION BIOSCIENCES, INC.

1-for-3 reverse stock split effective July 7, 2025; post-split shares ~1,534,599.
Split intended to regain Nasdaq minimum bid price compliance; CUSIP changed to 76135L705.
PRIME Phase 1b study of Gemini in CKD patients: enrollment expected to complete July 2025; topline data anticipated shortly after.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

REVELATION BIOSCIENCES, INC.: Filed Certificate of Amendment to effect a 1-for-3 reverse stock split (effective 2025-07-07).

Change: charter amendment
Effective: 2025-07-07

Exact text from the filing

the Company filed a Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) effective on July 7, 2025, which effected a 1-for-3 reverse stock split as of 12:01 a.m. Eastern Standard Time on July 7, 2025

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-094789

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.